Last reviewed · How we verify
Ciprodex
Ciprodex, marketed by St. Paul's Hospital in Canada, is an established drug with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Ciprodex |
|---|---|
| Also known as | ciprofloxacin 0.3% / dexamethasone 0.1%, ciprofloxacin and dexamethasone |
| Sponsor | St. Paul's Hospital, Canada |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Manipulating the Microbiome in IBD by Antibiotics and FMT (NA)
- FST-201 in the Treatment of Acute Otitis Externa (PHASE3)
- Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa (PHASE3)
- FST-201 In The Treatment of Acute Otitis Externa (PHASE3)
- N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media (PHASE4)
- Otiprio Versus Ciprodex Tympanostomy Tube Outcomes (PHASE4)
- Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes (PHASE2)
- Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprodex CI brief — competitive landscape report
- Ciprodex updates RSS · CI watch RSS
- St. Paul's Hospital, Canada portfolio CI